Ingrowth of aorta wall into stent grafts impregnated with basic fibroblast growth factor: a porcine in vivo study of blood vessel prosthesis healing  by van der Bas, J.M.Annemieke et al.
Ingrowth of aorta wall into stent grafts
impregnated with basic fibroblast growth factor:
A porcine in vivo study of blood vessel
prosthesis healing
J. M. Annemieke van der Bas, MD,a,b Paul H. A. Quax, PhD,a,b Arjen C. van den Berg, BSc,a Michel
J. T. Visser, PhD,b Edwin van der Linden, MD,c and J. Hajo van Bockel, PhD, MD,b Leiden, The
Netherlands
Objective: Endovascular aneurysm repair is an alternative treatment of abdominal aortic aneurysm. The procedure is less
invasive, and morbidity and most probably mortality are reduced. However, some problems, such as endoleakage, are yet
to be resolved. Endoleakage can occur after graft migration, as a result of insufficient fixation of the stent graft. One cause
is deficient healing between the aortic neck and the stent graft. We hypothesize that better healing, achieved by induction
of vascular cell ingrowth into the graft material, results in better graft fixation. Previously we demonstrated ingrowth of
neointima into the graft material if the stent graft is impregnated with a coat of basic fibroblast growth factor (bFGF),
heparin, and collagen. In this study we evaluated healing with bFGF-heparin-collagen–coated stent grafts in vivo.
Methods: In 4 pigs, 32 endovascular stent grafts, manufactured from standard Dacron and Gianturco Z-stents, were placed
in the aorta. The stent grafts were impregnated with either bFGF-heparin containing collagen (n  16) or control
collagen (n  16). After 4 and 8 weeks animals were killed, and ingrowth and healing of the stent grafts were
macroscopically and electron microscopically evaluated.
Results: After 8 weeks all bFGF-impregnated stent grafts demonstrated ingrowth of tissue and healing between the graft
and the aorta, whereas the control nonimpregnated stent grafts showed no ingrowth. Microscopic evaluation demon-
strated -smooth muscle actin–positive cells, most probably smooth muscle cells or myofibroblasts, growing from the
vascular wall through the graft material.
Conclusion: A Dacron prosthesis impregnated with collagen, heparin, and bFGF induced graft healing in an in vivo pig
model, in contrast to nonimpregnated stent grafts. This in vivo study confirms our previous findings in vitro. These
results indicate that healing between Dacron and the aorta can be achieved, and suggest that type I endoleakage may be
resolved by inducing healing between the aortic wall and the prosthesis with graft material containing growth factor. (J
Vasc Surg 2004;39:850-8.)Endovascular aortic aneurysm repair (EVAR) has been
in development for approximately 10 years. After an exper-
imental period, EVAR has now been accepted by many as
an alternative to conventional surgery. After use of EVAR
for several years, endoleakage early and late after the oper-
ation is still a problem. Endoleakage is defined as leakage at
the proximal stent of the endovascular prosthesis or as
backflow into the aneurysm through one of the lumbar
arteries.1 It is the result of an insufficient seal between the
endografts and the vessel wall. One reason for this problem
is impaired healing of the endograft to the vessel wall. This
hypothesis has been demonstrated by others.2-4 However,
it is also known from experimental work performed in the
1960s and from clinical observations that Dacron graft
material and the (aortic) vessel wall never heals adequately.5
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doi:10.1016/j.jvs.2003.11.045850The risk of endoleakage is that the aneurysm sac can be
pressurized. Consequently, the risks for expansion of the
aneurysm and even of rupture remain. Endoleakage is
sometimes caused by stent-graft migration,1,6-9 and the
phenomenon contributes to the high proportion of pa-
tients, as many as 27%, with various types of endoleak-
age.8,10-13
We hypothesized that improved healing and ingrowth
of vascular cells into the prosthesis material would improve
fixation of the endograft. To induce healing between the
prosthesis and the aortic wall, an impregnated vascular
prosthesis would be used, capable of releasing a growth
factor that stimulates cells in the aortic wall. This may result
in ingrowth of cells in the prosthesis and in stronger fixation
between the graft and the aorta. Previously, in in vitro
experiments with an aorta organ culture model of human
and pig aorta, we demonstrated that ingrowth of vascular
cells into graft material could be achieved with use of basic
fibroblast growth factor (bFGF).14 A neointima was in-
duced in approximately 4 weeks. Furthermore, we demon-
strated that impregnating the Dacron prosthetic material
with a collagen coating containing heparin and bFGF re-
sulted in slowly controlled release of bFGF over 5 weeks
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broblasts into the porous prosthetic material, which re-
sulted in healing and fixation of Dacron to the aortic wall.
Although we suggested that bFGF impregnation of
vascular prosthesis material is a successful approach to
stimulate graft healing in vitro, in vivo application of such
an approach may be met with several complications. Little
is known, for example, on the effect of variables in vivo,
such as blood flow, blood pressure, and vessel wall stress, on
ingrowth in vivo and on the washout effect of this growth
factor from the blood flow. Therefore we here address the
question of whether induction of neointima is possible in
vivo, and consequently whether cellular ingrowth and graft
healing in vivo occur.
In this study we tested the healing of bFGF-impreg-
nated collagen-coated stent grafts after endovascular deliv-
ery in the aorta in a porcine animal model in vivo. In
addition, we studied the ingrowth of vascular cells from the
aorta into the endovascular stent grafts.
MATERIAL AND METHODS
Study design. The effect of impregnation of collagen-
coated stent grafts with bFGF was compared with that with
nonimpregnated control stent grafts. Thirty-two stent
grafts, 16 impregnated with collagen and bFGF and 16
controls, were implanted in the aortas of four pigs. Before
the operation the length and diameter of the aortas were
measured at various levels with digital subtraction angiog-
raphy. On the basis of these measurements, each stent was
custom made to guarantee oversizing of 10% of the stent
graft with respect to the site of deployment in the porcine
thoracic or abdominal aorta. All stents were made for a
specific location in the aorta, as determined with the angio-
graphic information. All stent sizes were unique. Because
small changes may have occurred, the oversizing, as mea-
sured after hand-sewing, varied between 10% and 15%.
Two animals each were killed at 4 and 8 weeks. Healing of
the stent graft was subsequently analyzed macroscopically,
microscopically, and with scanning and electron microscopy.
Stent grafts. The stent grafts were Gianturco Z-stents
made of stainless steel (Cook, Denmark) and standard
Dacron fabric (Vascutek; Renfrewshire, England), which
we impregnated with collagen. We chose to test standard
graft material first, because it is likely that this material,
rather than material with greater pore size, is used for
applications in human beings. The self-expanding stents
were 4 cm in diameter and 2.5 cm long. The diameter of
the stent graft was determined according to that of the
Dacron fabric tube, which varied from 0.9 to 1.8 cm,
depending on the aortic diameter. Pre-procedural angio-
graphs showed average diameters of 16 mm for the thoracic
aorta and 10 mm for the abdominal aorta.
Vascular prosthetic material was standard woven Da-
cron fabric used for reconstructive surgery. Under sterile
conditions the Dacron vascular prosthetic material was
impregnated with collagen, as described.14-16 Type I insol-
uble collagen, derived from bovine Achilles tendon (Sigma,
St Louis, Mo), was swollen in acetic acid solution. Themixture was dispersed with crushed ice in a blender, then
homogenized (Ultra-Turrax T25; IKA Labortechnik,
Staufen, Germany). The resulting slurry was filtered
through a series of filters (Cellector Screen; Bellco,
Feltham, England) with pore size decreasing from 140 m
to 10 m, and mounted in 47-mm diameter disk filter
holders (Swinnex; Millipore, Etten-Leur, The Nether-
lands). After de-aeration at a pressure of 0.06 mbar, the
resulting suspension was plastered as a film on small pieces
of Dacron in sterile Petri dishes and dried at room temper-
ature in a sterile flow cabin. The collagen-impregnated
Dacron was cross-linked with N-(-3-dimethylaminopro-
pyl)-N-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide. The cross-linking was carried out in
2-morpholinoethane sulfonic acid buffer, to minimize hy-
drolysis of EDC. The cross-linking was completed, and
stopped by washing the impregnated Dacron with 0.1M of
Na2HPO4 solution.
After repeated washing with sterile water the Dacron,
impregnated with cross-linked collagen and heparin (hep-
arin sodium salt; Bufa Chemie, Castricum, The Nether-
lands) was bound to the prosthetic material, as de-
scribed.14,15
After this procedure the collagen-heparin–impregnated
Dacron fabric was washed with a solution of Na2HPO4,
NaCl, and, finally, distilled water. The binding of bFGF was
carried out after incubating the collagen-heparin–impreg-
nated Dacron fabric in phosphate-buffered saline solution
(PBS). After blotting dry, the films were incubated with
500 ng of bFGF in PBS containing 1 mg/mL of bovine
serum albumin at room temperature. Previous experiments
in vitro have shown that the bFGF released at this point was
5 to 8 ng per 24 hours, for 28 days.14
After impregnation of the Dacron fabric with either
“plain” collagen or bFGF-coated collagen, a stent graft was
constructed. Dacron tubes 2.5 cm long and varying in
diameter from 0.9 to 1.8 cm were hand-sewn with 6-0
vascular sutures (Gore-Tex) to the Gianturco stents. Vari-
ous calipers were used to guarantee that the diameter of the
stent graft was oversized by 10% compared with the aortic
diameter at the intended deployment site.
Release of bFGF from the collagen-impregnated Da-
cron fabric was analyzed after manipulation of the coated
stent grafts before and after the stent grafts were pushed
through the sheath of the delivery system. The release of
bFGF was evaluated with a test in which every 24 hours a
sample was obtained from the culture media in which the
collagen-heparin-bFGF–impregnated Dacron fabric was
placed. Every 24 hours the medium was replaced after the
sample was taken. The concentration of bFGF in the sam-
ples was determined with a sandwich enzyme-linked immu-
nosorbent assay (Quantikine bFGF ELISA; R&D Systems,
Abingdon, England).
Animals. All animal experiments and animal care were
performed according to the directives of the Ethical Com-
mittee for Animal Experimentation at Leiden University
Medical Center.
ment
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months. Identification was accomplished with ear labels.
The average weight of the animals at the time of the
procedure was 58.7  2.3 kg. The average weight of the
pigs killed at 4 weeks was 62.1 1.6 kg, and of those killed
at 8 weeks was 68.3  1.7 kg. All pigs received oral
anticoagulation therapy with warfarin sodium (Coumadin)
after the operation, to prevent thrombosis and guarantee
patency of the stent graft. Every week blood was drawn.
The average international normalized ratio for all pigs was
2.3  0.2. For each intervention the pigs were anesthe-
tized. After premedication with azoperone (2 mg/kg) and
atropine (0.05 mg/kg), the pigs were anesthetized with
thiopental (10 mg/kg IV), an endotracheal tube was
placed, and the lungs were ventilated with NO2 60%/O2
40%/isoflurane 0.5% to 3%. Muscle relaxation was obtained
with pancuronium bromide (Pavulon; 4-6 mg IV).
Operative technique. The procedure was performed
in the animal laboratory under fluoroscopy. Through a
midline incision the abdominal aorta was dissected, and a
small arteriotomy was made for introduction of the delivery
system, which was a 20F endovascular sheath (Cook).
Through the 20F sheath, eight stent grafts were introduced
Fig 1. X-ray control of placeand deployed in the aorta in sequence from the thoracic level
to just proximal to the aortic bifurcation. To prevent the effect
of bFGF upstream in the aorta on more downstream located
stent grafts, the stent grafts were deployed in a specific se-
quence; the four control stent grafts were inserted in the
thoracic aorta and subsequently more downstream, and the
bFGF-impregnated stent grafts were inserted in the aorta
below the diaphragm. Thus each pig could act as its own
control. The location, deployment, and apposition were
visualized with fluoroscopy before the operation was com-
pleted (Fig 1). Subsequently all incisions were closed.
Harvesting of the stent grafts and aorta. The pigs
were killed after 4 (n  2) and 8 (n  2) weeks. After
anesthetizing a pig, a midline incision was made and the
thoracic and abdominal aorta was dissected. The pig was
euthanized with potassium chloride, and subsequently the
aorta was removed completely. After retrieving the aorta,
all stent grafts were identified and dissected for macroscopic
and microscopic analysis, including standard microscopy
and scanning, and transmission electron microscopy. The
samples of aortic wall and Dacron graft material for analysis
were cut from the stent grafts between the Z-stent. Trian-
gular samples were obtained without any metal from the
of endovascular stent grafts.
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for microscopic evaluation impossible.
Histologic analysis. Paraffin-embedded tissue was
sectioned at 6 m. After dehydration, sections were used
either for histochemistry or immunohistochemistry. For
measurement of intima thickness, sections were stained
with hematoxylin, eosin, and saphran. Sections used for
immunohistochemistry were incubated with 0.3% H2O2
and 0.1% sodium azide in PBS for 15 minutes, to eliminate
endogenous peroxide activity, and were rinsed with PBS.
Sections were incubated overnight at 4°C with monoclonal
antibodies. To identify smooth muscle cells a monoclonal
antibody was used that recognizes smooth muscle -actin
(Sigma) at a dilution of 1:750. Bound monoclonal antibod-
ies were detected with horseradish peroxidase–conjugated
rabbit anti-mouse antibodies (1:300; DAKO, Glostrup,
Denmark). All antibodies were diluted in PBS with 0.1%
bovine serum albumin. The sections were exposed for 4
minutes to 0.04% diaminobenzidine tetrahydrochloride in
0.05 mol/L of Trismaleate buffer (pH 7.6) with 0.006%
H2O2. Sections were briefly counterstained with
hematoxylin.
Image analysis. To determine the amount of neoin-
tima formation, morphometry was performed with image
analysis (QWin; Leica Imaging Systems, Cambridge, En-
gland) in histologic sections of the vessel segments. The
neointima area is given in square millimeters per micro-
scopic field.
Electron microscopy. Scanning electron microscopy
was performed with segments of the harvested stents,
which were fixed in 0.05 mol/L of phosphate- buffered
(pH 7.0) 2% glutaraldehyde for 16 to 20 hours, and rinsed
in the same buffer. Further fixation in 1% OsO4 in 0.1M
sodiumcacodylate (pH 7.4) for 2 hours was followed by
dehydration through 70% to absolute acetone. Dehydrated
sections were critical point dried, sputter-coated with gold,
and examined with a Jeol 6400 scanning electron
microscope.
Transmission electron microscopy was used for proper
identification of the ingrowing vascular cells. Segments of
the isolated stents with aorta were fixed in a 0.1M sodium-
cacodylate (pH 7.4) buffered mixture of 2% paraformalde-
hyde and 1% glutaraldehyde for 2 hours. Further fixation in
1% OsO4 in 0.1M sodiumcacodylate (pH 7.4) for 2 to 24
hours (until stained black) was followed by dehydration
through 70% to absolute alcohol and embedding in Epon.
Ultra-thin (70-nm) sections were examined with a Jeol 100
CX or Jeol 1010 electron microscope, with lead citrate and
uranyl acetate used for contrast.
RESULTS
Preparation of stent grafts. The effect of manipula-
tion of the coated stent grafts on bFGF release from the
coating was analyzed by measuring the release of bFGF
from a coating before and after the stent graft was pushed
through the sheath of the delivery system. This manipula-
tion caused only a marginal, nonsignificant decrease in the
amount of bFGF on the stent graft (6.2 1.1 ng/24 hr vs5.9  0.9 ng/24 hr). These results were similar to those
observed previously in our in vitro study of bFGF release.14
Macroscopy. Macroscopic analysis revealed adhesion
of the prosthesis material to the aorta wall with bFGF-
impregnated Dacron stent grafts, whereas no adherence
between the stent graft and the aorta was observed in the
control stent grafts. Furthermore, it could clearly be ob-
served macroscopically that with the bFGF-impregnated
collagen-coated stent grafts both the metal parts of the
stent and the Dacron graft material at the luminal side were
completely covered with a white shiny tissue (Fig 2, A).
There was no space between the Dacron and the aorta,
indicating that the Dacron stent graft had completely
healed to the vessel wall. During dissection of the stent
graft to obtain samples for microscopy, the Dacron proved
to be firmly attached to the aorta. On the other hand, the
control stent grafts were not covered with any tissue on the
luminal side, and there appeared to be a space between the
Dacron and aortic wall, which was filled with loose throm-
bus (Fig 2, B). Moreover, during careful dissection for
microscopy the Dacron could easily be detached from the
aorta, indicating the absence of any healing.
Incorporation of the stents was macroscopically ob-
served after 4 weeks in the bFGF-impregnated stent grafts.
No discernible difference between the results obtained at 4
and 8 weeks was observed. At the site of the bFGF-impreg-
nated collagen-coated stent graft no stenosis due to exces-
sive neointima was observed at either 4 or 8 weeks.
Histologic analysis. Since none of the histologic anal-
yses revealed any differences regarding the amount of cells
and the type of cells growing into the stents between the
4-week and 8-week groups for both bFGF-impregnated
collagen-coated and control stent grafts, the results are not
presented separately. Histologic analysis demonstrated that
when the animals were killed, at 4 and 8 weeks after the
initial operation, the bFGF-impregnated Dacron stent
grafts were fully incorporated into the vessel wall, whereas
the control grafts were not fixed. Detailed analysis revealed
that in the coated stent grafts the prosthetic graft material
was not only covered with tissue, but cells grew completely
throughout the Dacron fabric (Fig 3, A). By 4 weeks
almost all the collagen coating in the bFGF-impregnated
stent grafts had disappeared; the control grafts showed only
an inflammatory reaction (Fig 3, B). A large number of cells
on the luminal side of the aorta and within and through the
Dacron graft were observed. These cells proved to be
-smooth muscle actin-positive cells, most probably
smooth muscle cells or myofibroblasts. Further evaluation
of this neointima with elastin and HES staining showed
that elastin and collagen were absent in the neointima. In
addition, at histologic analysis no capillaries were found in
the neointima. Endothelial cells could not be identified
histologically on the luminal side of the stent graft. How-
ever, it should be acknowledged that endothelial cells could
have been lost at dissection or processing of the samples.
At image analysis, neointima development and in-
growth was quantified. After 4 weeks, there appeared to be
a significant increase in the neointima in the coated group
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bFGF-impregnated stent group was 0.34 0.021 mm2 per
cross section, whereas in the control group the neointima
was 0.11  0.015 mm2 (P  .05; Fig 4). Thereafter, the
additional increase in the amount of intimal hyperplasia up
to 8 weeks appeared to be minimal. This slight increase in
neointima from 4 to 8 weeks was not statistically significant.
The control stent grafts were only covered with a layer
of thrombus material, both between the vessel wall and the
stent graft, but also on the luminal side of the stent graft.
When samples were taken, there appeared to be no adher-
ence between the stent graft and the aortic wall. Histologic
image analysis demonstrated only erythrocytes between the
aortic wall and the stent graft. No cells were observed
growing through the Dacron fabric. There were no signs of
ingrowth, healing, or fixation.
Scanning electron microscopy. Scanning electron
microscopy revealed a pattern similar to the macroscopic
appearance. bFGF-impregnated stent grafts demonstrated
a fully incorporated stent graft, covered with smooth mus-
Fig 2. Macroscopic difference between stents impregna
A, Impregnated stent demonstrates a tissue layer on the l
stent exhibits thrombus.cle cells or myofibroblasts, whereas in the control stent
grafts no ingrowth was observed (Fig 5, A and B). SEM
analysis showed no differences between 4 and 8 weeks in
the Bfgf-impregnated stent grafts. In the control group
only red blood cells and fibrin covered the stent graft. Both
the Dacron and metal stents were visible.
Transmission electron microscopy. Transmission
electron microscopy analysis of the bFGF-impregnated
stent grafts demonstrated, on the luminal side, endothelial
cells, identified by morphologic features. In the same layer,
the neointima, there was an abundance of proliferating cells
with a long, stretched appearance, which were identified as
young myofibroblasts rather than smooth muscle cells,
although the morphologic differences between these two
cell types are minimal. All the cells and tissues were com-
pletely grown into the Dacron (Fig 6).
DISCUSSION
In a previous in vitro study we demonstrated that bFGF
coating of vascular Dacron graft material induced ingrowth
r not impregnated with basic fibroblast growth factor.
al side and across the proximal landing zone. B, Controlted o
umin
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study is that ingrowth and healing of endovascular stent
grafts in vivo in pigs can be accomplished by impregnating
the grafts with collagen to which bFGF is bound and slowly
released over several weeks after implantation.
Fig 3. Macroscopic analysis of stents. A, Stent impregn
neointima growing through the Dacron fabric. B, Contr
the aorta.The main objective of our manipulation of stent grafts
was to improve the fixation, now primarily based on stents,
into a more permanent fixation, independent from stents.
However, the ingrowth or healing does not mean fixation.
We have not yet quantified the mechanical quality of our
with basic fibroblast growth factor clearly demonstrates
nt demonstrates some thrombus, and no attachment toated
ol ste
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pregnated stent grafts were tightly fixed to the aortic wall,
and it appeared to be impossible to separate these from the
aortic wall manually, whereas the control stents were never
attached and could easily be separated from the aorta. This
Fig 4. Measurement of the neointima at 4 and 8 weeks after stent
placement. There is no difference in neointima induction in stents
impregnated with basic fibroblast growth factor (bFGF) at 4 and 8
weeks. Control stents did not induce any significant neointima.
Fig 5. Scanning electron microscopy of stent grafts. Stent impreg-
nated with basic fibroblast growth factor A, demonstrates a tissue
layer, whereas the control stent B does not.mechanical difference between the two groups can be ex-
plained from the histologic findings. The bFGF-impreg-
nated stent grafts demonstrated a neointima without
thrombus, whereas in the controls there was only thrombus
between the stent graft and the vessel wall. This suggests
that formation of the neointima starts directly after implan-
tation of the stent graft. This could lead to direct sealing of
the proximal landing zone of the stent graft, and would
therefore not lead to any thrombus formation between the
vascular wall and the stent graft, or the thrombus could
have functioned as a matrix for the neointima to grow in the
stents.
The findings were assessed both macroscopically and
microscopically. Macroscopically, all bFGF-impregnated
stent grafts demonstrated ingrowth of cells from the vessel
wall, whereas the control stent grafts did not demonstrate
any ingrowth. This effect was already present at 4 weeks
after implantation in the pigs, and did not quantitatively or
qualitatively change after another 4 weeks. Microscopically,
this effect was confirmed. There was abundant evidence of
ingrowth of neointima cells growing between the aortic
wall and the bFGF-impregnated stent graft, and growing
through and on the luminal side of the Dacron fabric.
These findings were also confirmed at scanning and trans-
mission electronic microscopy. The cells growing through
the Dacron were identified as stretched, young cells that
were -actin-positive cells. These morphologic characteris-
tics suggest that these cells were most probably myofibro-
blasts originating from the media of the wall of the aorta.
However, the type and origin of these cells are difficult to
determine exactly,17 and we identified these cells at trans-
mission and scanning electron microscopy as smooth mus-
cle–like cells or young smooth muscle cells.
Although the graft material was incorporated, there
was no evidence of covering with endothelial cells on the
luminal side in sections analyzed at light microscopy with
von Willebrand staining. However, transmission electron
microscopy demonstrated endothelial-like cells on the sur-
face. Therefore we conclude that healing of the stent grafts
occurred with covering of the stent with endothelial-like
cells. We believe we could not demonstrate endothelial cells
at immunohistologic light microscopy because of the fixa-
tion process. Endothelial cells can be easily removed during
handling of the incorporated stent grafts.18
Although the bFGF-impregnated grafts were placed
downstream from the control grafts, we anticipated the
possibility that the release of bFGF from downstream grafts
could have had an effect on healing of the downstream
grafts by concentration of bFGF in circulating blood. We
found no evidence for any such possible effect. First, the
half-life of bFGF in circulating blood is short, between 40
and 60 minutes, which results, in theory, in a systemic
bFGF concentration that is not detectable. Second, we also
measured the bFGF systemic concentration as a control of
the stent design, and no bFGF was detected at any of time
interval. Finally, by placing the two stent designs in one
animal we were able to eliminate any interspecies variation.
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incorporated in animals that are young and healthy.19 For
this reason we chose the period of 4 to 8 weeks for our
experiments, to prevent the natural healing in the pig
model. The pig vascular model is well-known for its capa-
bility of incorporating and endothelializing conventional
vascular prostheses after a few months. To prevent any
natural ingrowth or healing by the pigs, we chose the
relatively short periods of 4 and 8 weeks before the animals
were killed. These relatively short periods prevented the
possibility of studying other facets of stent grafts proce-
dures, for example, migration. Migration will be evaluated
in our next studies. The observation that the control endo-
vascular stents grafts did not show any incorporation in the
pig aorta, except for a minor inflammatory reaction, even
after 8 weeks, supports our conclusion that the effects can
be exclusively attributed to the growth factor.
It is important for optimal fixation of the stent graft
that both the stent and the Dacron fabric are well-incorpo-
rated in the vessel wall. It is universally accepted that
incorporation of metal stents in the vessel wall is superior to
that of graft material. But it is doubtful that fixation of
stents is sufficient to prevent migration if the aorta dilates.
Mangell et al20 studied the fixation of endografts in pigs.
Fig 6. Transmission electron microscopy of stent impre
the Dacron fabric is covered with tissue.They implanted Gianturco self-expandable stents and
Palmaz balloon-expandable stents. In their study the pigs
were killed after 18 weeks, enabling the weight to increase
from a mean of 21 kg to 95 kg. These authors found that
self-expandable stents continued to show good apposition
to the vessel wall, whereas most of the balloon-expandable
stents were partially detached from the aortic wall, indicat-
ing insufficient incorporation under circumstances of dila-
tion of the aorta as a result of growth of the animals.20
It is also well known that incorporation of Dacron graft
material at the level of the suture line almost never occurs in
the older patient with atherosclerosis who undergoes vas-
cular reconstruction to treat aneurysmal or occlusive dis-
ease. Since the beginning of vascular surgery it has been
well demonstrated that the integrity of an anastomosis
between an artery and a vascular prosthesis depends on the
suture line as long as the prosthesis remains in patient.5
This may be one of the causes of false aneurysm formation,
which may occur in as many as 20% of those patients still
alive after long-term follow-up of 15 years.21,22 It has also
been well demonstrated that healing of endovascular grafts
is absent in human beings. Malina et al2 retrieved 23
Dacron stent grafts from patients treated for an aortic
aneurysm 9 months (range, 1-31 months) after insertion.
d with basic fibroblast growth factor clearly shows thatgnate
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poorly organized blood components persisted up to 2-1/2
years after implantation of the stent graft. No firm incorpo-
ration of the grafts was observed, and only a friable neoin-
timal layer covered parts of the luminal aspect of the grafts.
They concluded that endovascular healing provides poor
fixation of Dacron stent-grafts in human beings.2 This
absence of healing may be responsible for part of the
migration of endografts used to treat aneurysms. Recently,
one of the pioneers of vascular surgery, very familiar with
the absence of healing with conventional vascular prosthe-
sis as established in the 1960s, warned against making the
same underestimation of the problem of inadequate heal-
ing and its consequences as was made in the past.4 The
results from studies obtained in animals cannot be directly
extrapolated to human beings. However, previously we
demonstrated that bFGF can induce ingrowth of aortic
cells into Dacron graft material in human atherosclerotic
aorta, suggesting that this effect may also be achieved in
appropriately impregnated endografts.
We used bFGF because of its capacity to induce intimal
hyperplasia, which implies the risk for inducing stenosis in
the treated vessel segments. However, no stenosis was
found in the pig aortas after 8 weeks. Although stenosis is
not likely over the long term, because collagen impregna-
tion as well as bFGF release disappears after 4 weeks, studies
should be performed to address this issue over a prolonged
period.
In conclusion, we believe that successful induction of
ingrowth of vascular cells into stent grafts and the subse-
quent healing of endovascular stent grafts may help reduce
migration of the stent grafts. The incidence of endoleak at
the proximal and distal landing zones of endovascular stent
grafts can be reduced. On the other hand, cellular ingrowth
is not equivalent to the quality of fixation and migration,
and further experiments are required to prove the clinical
effects. This might represent a step forward in the clinical
treatment of human abdominal or thoracic aneurysms with
EVAR, because known complications such as endoleak,
stent graft migration, and risk for subsequent rupture of the
aneurysm may be reduced or even prevented.21
REFERENCES
1. White GH, Yu W, May J, Chaufour X, Stephen MS. Endoleak as a
complication of endoluminal grafting of abdominal aortic aneurysms:
classification, incidence, diagnosis, and management. J Endovasc Surg
1997;4:152-68.
2. Malina M, Brunkwall J, Ivancev K, Jonsson J, Malina J, Lindblad B.
Endovascular healing is inadequate for fixation of Dacron stent-grafts in
human aortoiliac vessels. Eur J Vasc Endovasc Surg 2000;19:5-11.
3. Guidoin R, Marois Y, Douville Y, King MW, Castonguay M, Traore A,
et al. First-generation aortic endografts: analysis of explanted Stentor
devices from the EUROSTAR Registry. J Endovasc Ther 2000;7:105-
22.4. Szilagyi DE. The problem of the healing of intraaortic arterial prosthe-
ses in the treatment of abdominal aortic aneurysms. J Vasc Surg 2001;
33:1283-5.
5. Edwards WS, Dalton D JR. Anastomoses between synthetic graft and
artery. Arch Surg 1963;86:477-9.
6. Chuter TA, Faruqi RM, Sawhney R, Reilly LM, Kerlan RB, Canto CJ,
et al. Endoleak after endovascular repair of abdominal aortic aneurysm.
J Vasc Surg 2001;34:98-105.
7. Schurink GW, Aarts NJ, van Baalen JM, Schultze Kool LJ, van Bockel
JH. Stent attachment site-related endoleakage after stent graft treat-
ment: an in vitro study of the effects of graft size, stent type, and
atherosclerotic wall changes. J Vasc Surg 1999;30:658-67.
8. Schurink GW, Aarts NJ, van Bockel JH. Endoleak after stent-graft
treatment of abdominal aortic aneurysm: a meta-analysis of clinical
studies. Br J Surg 1999;86:581-7.
9. Schurink GW, Aarts NJ, van Baalen JM, Chuter TA, Schultze Kool LJ,
van Bockel JH. Late endoleak after endovascular therapy for abdominal
aortic aneurysm. Eur J Vasc Endovasc Surg 1999;17:448-50.
10. de Virgilio C, Bui H, Donayre C, Ephraim L, Lewis RJ, Elbassir M, et
al. Endovascular vs open abdominal aortic aneurysm repair: a compar-
ison of cardiac morbidity and mortality. Arch Surg 1999;134:947-50.
11. Dorffner R, Thurnher S, Polterauer P, Kretschmer G, Lammer J.
Treatment of abdominal aortic aneurysms with transfemoral placement
of stent-grafts: complications and secondary radiologic intervention.
Radiology 1997;204:79-86.
12. Moore WS, Kashyap VS, Vescera CL, Quinones-Baldrich WJ. Abdom-
inal aortic aneurysm: a 6-year comparison of endovascular versus trans-
abdominal repair. Ann Surg 1999;230:298-306.
13. Walker SR, Macierewicz J, MacSweeney ST, Gregson RH, Whitaker
SC, Wenham PW, et al. Mortality rates following endovascular repair of
abdominal aortic aneurysms. J Endovasc Surg 1999;6:233-8.
14. van der Bas JM, Quax PH, van den Berg AC, van Hinsbergh VW, van
Bockel JH. Ingrowth of aorta vascular cells into basic fibroblast growth
factor–impregnated vascular prosthesis material: a porcine and human
in vitro study on blood vessel prosthesis healing. J Vasc Surg 2002;36:
1237-47.
15. Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling
T, et al. Binding and release of basic fibroblast growth factor from
heparinized collagen matrices. Biomaterials 2001;22:2291-9.
16. Wissink MJ, Beernink R, Pieper JS, Poot AA, Engbers GH, Beugeling
T, et al. Immobilization of heparin to EDC/NHS-crosslinked collagen:
characterization and in vitro evaluation. Biomaterials 2001;22:151-63.
17. Carmeliet P. Cardiovascular biology: creating unique blood vessels.
Nature 2001;412:868-9.
18. Sprague EA, Luo J, Palmaz JC. Endothelial cell migration onto metal
stent surfaces under static and flow conditions. J Long Term Effects
Med Implant 2000;10:97-110.
19. Quinones-Baldrich WJ, Moore WS, Ziomek S, Chvapil M. Develop-
ment of a “leak-proof,” knitted Dacron vascular prosthesis. J Vasc Surg
1986;3:895-903.
20. Mangell P, Malina M, Vogt K, Lindh M, Schroeder T, Risberg B, et al.
Are self-expanding stents superior to balloon-expanded in dilating
aortas? an experimental study in pigs. Eur J Vasc Endovasc Surg
1996;12:287-94.
21. Edwards JM, Teefey SA, Zierler RE, Kohler TR. Intraabdominal para-
anastomotic aneurysms after aortic bypass grafting. J Vasc Surg 1992;
15:344-50.
22. van den Akker PJ, Brand R, van Schilfgaarde R, van Bockel JH, Terpstra
JL. False aneurysms after prosthetic reconstructions for aortoiliac ob-
structive disease. Ann Surg 1989;210:658-66.
Submitted May 11, 2003; accepted Nov 28, 2003.
Available online Feb 6, 2004.
